Today's Core ThemeThe market is in a valuation triage phase. With rates holding at restrictive levels and inflation sticky in services, investors are no longer paying for growth at any price. Instead, capital is rotating toward businesses with visible cash flows and defensible margins. The spread between the cheapest and most expensive large caps is widening: Berkshire Hathaway trades at 13.5x earnings with a 2.2% FCF yield, while Palantir commands 160x earnings on a 0.4% FCF yield. That 12x FCF yield gap is the market's way of pricing certainty. Sector-wise, energy and staples are neutral-weighted as investors wait for demand signals, while healthcare and select tech names with pricing power attract bids. The message: multiples matter again. Stock Deep-Dive: BRK-BBerkshire Hathaway is the standout value anchor in today's data. At $538.99, it trades at 13.53x earnings with a 2.2% free cash flow yield and a health score of 8/10. That's a rare combination of scale, balance-sheet strength, and a valuation that assumes little perfection. The conglomerate's insurance float and operating earnings provide a natural hedge against volatility, while its cash pile remains a call option on dislocation. With no DCF fair value flagged, the market is essentially pricing Berkshire at a discount to its own historical average—a signal worth noting. Eli Lilly is the growth counterpoint. At $1,270.75, it carries a 42.5x P/E and a thin 0.5% FCF yield, but the market is paying for pipeline durability in GLP-1 therapies. The health score of 8/10 suggests the balance sheet can support the multiple, but the margin for error is narrow. If script trends or reimbursement headlines wobble, the stock is vulnerable to multiple compression. Sector Radar & Key LevelsWatch the 10-year Treasury yield around 4.2%—a break above could pressure long-duration names like PLTR and AVGO. Broadcom (41.9x P/E, 1.7% FCF yield) is neutral but sits at the intersection of AI capex and cyclical semis; any guidance cut from hyperscalers would hit sentiment. ExxonMobil (22.9x P/E, 3.2% FCF yield) is the highest FCF yielder in the group, making it a proxy for energy inflation hedges. Walmart (42.5x P/E, 1.6% FCF yield) looks expensive for a staples name—watch consumer spending data for cracks. Upcoming catalysts: Berkshire's Q3 update (cash deployment), Lilly's obesity drug trial readouts, and Palantir's government contract renewals. The Investor TakeawayThis is not a market for indiscriminate beta. It's a market for balance. Berkshire offers a margin of safety with upside optionality; Lilly offers growth but demands patience and a strong stomach for volatility. Palantir's 160x multiple is a momentum bet, not a value investment—size accordingly. The neutral verdicts on XOM, WMT, and AVGO suggest waiting for better entries or clearer catalysts. In short: own cash flow, rent momentum, and keep dry powder for the next dislocation.
|